Interestingly, TRAP1 upregulation has been described in several human malignancies, with a prevalent glycolytic metabolism (i.e., colon, breast, lung, prostate, nasopharyngeal, and thyroid carcinomas) [65], and a proteomic analysis of the TRAP1 client protein network demonstrated that TRAP1 is co-expressed with most of its interactors in human colorectal carcinomas, and that the overexpression of TRAP1 and six of its client proteins is predictive of poor outcomes [80]. Here, TRAP1 is linked to colorectal carcinoma.